PHILADELPHIA, Dec. 19, 2025 (GLOBE NEWSWIRE) --
Cytokinetics, Inc. (NASDAQ: CYTK):
Grabar Law Office is investigating claims on behalf of shareholders of Cytokinetics, Inc. (NASDAQ: CYTK). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
If you purchased Cytokinetics, Inc. (NASDAQ: CYTK) shares prior to December 27, 2023, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/cytokinetics-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.
WHY? As alleged in a recently filed federal securities fraud class action complaint, Cytokinetics, Inc. (NASDAQ: CYTK), through certain of its officers made materially false and misleading statements on to the market, Specifically, on March 10, 2025, Cytokinetics disclosed that the U.S. Food and Drug Administration ("FDA") had decided not to convene an advisory committee meeting to review the Company's New Drug Application ("NDA") for aficamten. On May 1, 2025, Cytokinetics announced that the FDA had extended the Prescription Drug User Fee Act action date for aficamten's NDA from September 26, 2025 to December 26, 2025 in order to review a Risk Evaluation and Mitigation Strategy ("REMS") submitted at the FDA's request after the initial NDA filing, thereby disclosing that the Company had not included a REMS in the original NDA. Then, on May 6, 2025, Chief Executive Officer Robert I. Blum acknowledged that Cytokinetics had multiple pre-NDA meetings with the FDA to discuss safety monitoring and risk mitigation but chose to submit the NDA without a REMS, relying on labeling and voluntary education materials. These misleading statements and delayed disclosures caused the company and its shareholders significant harm.
WHAT YOU CAN DO NOW: If you purchased Cytokinetics, Inc. (NASDAQ: CYTK) shares prior to December 27, 2023, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/cytokinetics-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. $CYTK #Cytokinetics #CYTK
Holley Inc. (NYSE: HLLY) Class Action Survives Motion to Dismiss:
Grabar Law Office is investigating claims on behalf of shareholders of Holley, Inc. (NYSE: HLLY). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
Current Holley Inc. (NYSE: HLLY) shareholders who have held Holley shares since on or shortly after to July 21, 2021, or via holdings of Empower Ltd., can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever. If you would like to learn more about this matter, you are encouraged to visit https://grabarlaw.com/the-latest/holley-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.
Why? A federal securities fraud class action complaint has survived a motion to dismiss. That complaint alleges that Holley Inc. (NYSE: HLLY) f/k/a Empower Ltd., through certain of its officers and directors, made false and/or misleading statements and/or failed to disclose that: (i) as a result of Holley’s extensive focus on its direct-to-consumer (“DTC”) channel, Holley’s critically important relationships with its resellers and distributors, whose business made up the vast majority of Holley’s revenue, were suffering significant damage; (ii) Holley used discounting and other similar efforts to grow its DTC channel, which undermined the pricing discipline Holley historically had with its resellers and distributors, and further damaged Holley’s relationship with its resellers and distributors; (iii) as a result of Holley’s strained relationships with its resellers and distributors, those resellers and distributors were decreasing their purchases of Holley products, returning products already purchased at significant levels that were far above historical norms, and increasing their purchases of competitors’ products; (iv) Holley’s growing DTC channel could not offset the negative financial impact of Holley’s increasingly strained relationships with its resellers and distributors and, as a result, Holley’s critical relationship with resellers and distributors was deteriorating; (v) Holley had failed to successfully integrate and capture synergies from its numerous acquisitions, which left Holley with inefficient operations, excess costs, and inventory management problems; and (vi) Holley benefited from COVID-related stimulus money that temporarily boosted its sales and performance, and despite this unsustainable, temporary boost, defendants misled investors to believe the growth was sustainable and the result of persistent demand, and supportive of positive financial guidance.
The Court in the underlying securities fraud class action has determined that with respect to multiple statements made by company leadership, the Complaint “has pleaded the requisite level of falsity needed to survive dismissal by listing the statements and providing reasons why they were misleading or false.” The court further determined that the Complaint sufficiently pleaded allegations of falsity and scienter (knowledge of wrongdoing or intent to deceive, defraud, or act unlawfully, or with reckless indifference), as required for a prima facie case as to these claims.
What You Can Do Now: Current Holley shareholders who have held Holley shares since on or shortly after July 21, 2021, or via holdings of Empower Ltd., can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever. If you would like to learn more about this matter, you are encouraged to visit https://grabarlaw.com/the-latest/holley-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. $HLLY #HolleyInc #HLLT #Holley
Molina Healthcare, Inc. (NYSE: MOH):
Grabar Law Office is investigating claims on behalf of shareholders of Molina Healthcare, Inc. (NYSE: MOH). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
If you purchased Molina Healthcare, Inc. (NYSE: MOH), shares prior to February 5, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/molina-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085 to learn more.
WHY? As alleged in an underlying securities fraud class action complaint, Molina Healthcare, Inc. (NYSE: MOH), through certain of its officers, failed to disclose: (1) material, adverse facts concerning Molina Healthcare's "medical cost trend assumptions"; (2) that Molina Healthcare was experiencing a "dislocation between premium rates and medical cost trend"; (3) that Molina Healthcare's near term growth was dependent on a lack of "utilization of behavioral health, pharmacy, and inpatient and outpatient services"; and (4) as a result, Molina Healthcare's financial guidance for fiscal year 2025 was substantially likely to be cut.
WHAT YOU CAN DO NOW: If you purchased Molina Healthcare, Inc. (NYSE: MOH), shares prior to February 5, 2025 and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/molina-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. $MOH #Molina #MOH
WEBTOON Entertainment Inc. (NASDAQ: WBTN) – Shareholder Class Action Survives Motion to Dismiss:
Grabar Law Office is investigating claims on behalf of shareholders of WEBTOON Entertainment Inc. (NASDAQ: WBTN). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
If you purchased WEBTOON (NASDAQ: WBTN) shares on or shortly after the Company’s June 27, 2024, IPO, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/webtoon-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.
WHY? On November 14, 2025, the United States District Court for the Central District of California denied Defendants’ attempt to dismiss an underlying securities fraud class action complaint. In allowing the class action to proceed, the court determined that Plaintiff adequately alleged that WEBTOON misled investors about the condition of one of its most critical performance metrics—Monthly Active Users (“MAU”)—at the time of its IPO. The Court also held that Plaintiff plausibly alleged that WEBTOON’s risk disclosures and omission-based statements were misleading.
WHAT YOU CAN DO NOW: If you purchased WEBTOON Entertainment Inc. (NASDAQ: WBTN) shares on or shortly after the Company’s June 27, 2024 IPO, you are encouraged to visit https://grabarlaw.com/the-latest/webtoon-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. #WBTN #WEBTOON $WBTN
Attorney Advertising Disclaimer
Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: jgrabar@grabarlaw.com
